Evidence map›Paper›PMID 27014418›Full record

ArticleGenes & cancer2016

Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.

Sarah E Woodfield, Rong Jun Guo, Yin Liu, Angela M Major, Emporia Faith Hollingsworth, Sandra Indiviglio, Sarah B Whittle, Qianxing Mo, Andrew J Bean, Michael Ittmann and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Genes & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sarah E WoodfieldDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Rong Jun GuoDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; Department of Pathology, University of Alabama Birmingham, Birmingham, AL, USA.
Yin LiuDepartment of Neurobiology and Anatomy, The University of Texas Medical School & Graduate School of Biomedical Sciences, Houston, TX, USA; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Angela M MajorDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Emporia Faith HollingsworthDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Sandra IndiviglioDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Sarah B WhittleDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Qianxing MoDepartment of Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Andrew J BeanDepartment of Neurobiology and Anatomy, The University of Texas Medical School & Graduate School of Biomedical Sciences, Houston, TX, USA.
Michael IttmannDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; The Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX, USA.
Dolores Lopez-TerradaDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Peter E ZageDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USThe University of Texas at Austin · USUniversity of Alabama at Birmingham · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in OsteosarcR01CA149501 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KLEINERMAN, EUGENIE S · 2010 to 2015
$1.7M
The Role of Growth Factor Receptor Trafficking in TumorigenesisR01CA166749 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZAGE, PETER E. · 2013 to 2017
$1.7M
Bayesian Methods in Signal Transduction Network AnalysisR01LM010022 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LIU, YIN · 2011 to 2014
$901k
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA149501NCI NIH HHS R01 CA166749NLM NIH HHS R01 LM010022
6 · The paper itself

Abstract

backgroundUBE4B is an E3/E4 ubiquitin ligase whose gene is located in chromosome 1p36.22. We analyzed the associations of UBE4B gene and protein expression with neuroblastoma patient outcomes and with tumor prognostic features and histology.

methodsWe evaluated the association of UBE4B gene expression with neuroblastoma patient outcomes using the R2 Platform. We screened neuroblastoma tumor samples for UBE4B protein expression using immunohistochemistry. FISH for UBE4B and 1p36 deletion was performed on tumor samples. We then evaluated UBE4B expression for associations with prognostic factors and with levels of phosphorylated ERK in neuroblastoma tumors and cell lines.

resultsLow UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma and with worse outcomes in all patient subgroups. UBE4B protein expression was associated with neuroblastoma tumor differentiation, and decreased UBE4B protein levels were associated with high-risk features. UBE4B protein levels were also associated with levels of phosphorylated ERK.

conclusionsWe have demonstrated associations between UBE4B gene expression and neuroblastoma patient outcomes and prognostic features. Reduced UBE4B protein expression in neuroblastoma tumors was associated with high-risk features, a lack of differentiation, and with ERK activation. These results suggest UBE4B may contribute to the poor prognosis of neuroblastoma tumors with 1p36 deletions and that UBE4B expression may mediate neuroblastoma differentiation.

Indexed as

differentiationERKneuroblastomaretinoic acidUBE4B

Identifiers

PMID27014418
PMCPMC4773702
OpenAlexW2337047772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.